The arrival of Retatrutide ZPHC, at a concentration of 120mg, is sparking considerable interest within the weight loss community. This novel dual GIP and GLP-1 target medication appears to offer notable improvements in fat loss compared to previous therapies. Preliminary patient trials have demonstrated substantial decreases in body mass , potentia